Results.
In total, 19,681 patients were eligible for analysis in this study. During an average follow-up of 15 years, the event rates of each comorbidity differed significantly between the users and non-users of biologics with regard to cardiovascular comorbidity, metabolic comorbidity, rheumatologic comorbidity, and the miscellaneous comorbidity (all p<0.05). The usage of biologic agents in RA patients reduced the HR of cardiovascular comorbidities by 18%, metabolic comorbidities by 17%, rheumatology comorbidities by 36%, and miscellaneous comorbidities by 15% compared to those patients who did not use biologics. Oncology comorbidities and infection comorbidities were not affected by treatment with biologics (p>0.05).